Herceptin 600 mg S/C (Trastuzumab) — Targeted Therapy for HER2-Positive Breast Cancer Herceptin 600 mg S/C Injection contains trastuzumab, a targeted monoclonal antibody used to treat HER2-positive breast cancer and other HER2-positive tumors. The subcutaneous (S/C) formulation enables quick administration under the skin, typically once every three weeks, reducing treatment time compared with traditional IV infusions. Herceptin attaches to the HER2 receptor on cancer cells, blocking growth signals and recruiting immune responses to help eliminate malignant cells. This therapy is administered under strict medical supervision as part of an oncology treatment plan, often alongside chemotherapy or other targeted drugs. Regular monitoring of heart function and overall health is required due to cardiac and immune effects. Available in Pakistan from authorized oncology pharmacies and medical suppliers with prescription support, Herceptin 600 mg offers effective targeted cancer care when used as prescribed by an oncologist.